Dallas, TX: ReportsandReports announce AstraZeneca plc: PharmaVitae Profile Market Research Report in its Store.
Browse complete Report at: http://www.reportsandreports.com/reports/7951-astrazeneca-plc-pharmavitae-profile.html
This analysis examines the historical and forecast performance for AstraZeneca in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
• Benchmark AstraZeneca’s performance against key rivals in the prescription pharmaceutical sector
• Assess the commercial impact of AstraZeneca’s recent movement into the biologics market, spearheaded by its acquisition of MedImmune
• Analyse the exposure of AstraZeneca’s blockbuster portfolio to patent expiration and generic competition through to 2014
Table Of Contents
ABOUT DATAMONITOR HEALTHCARE
About the PharmaVitae team
Chapter 1 About this profile
PharmaVitae Explorer database
Chapter structure
Executive summary
Quarterly update
Company introduction
Company sales
Company financials
Key products
Data sourcing
Sales data
Analyst consensus
Chapter 2 Executive summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003-15
Financial performance, 2002-14
Note regarding full year 2009 financial data
AstraZeneca: PharmaVitae forecasts at a glance
Strategic insight
Highest material exposure to patent cliff in Big Pharma
Purity of blockbuster growth strategy facilitates high level of generic exposure
Overly dependent on small molecules
Exposed to cross-class therapeutic substitution
AstraZeneca cannot afford any more pipeline setbacks
MedImmune acquisition drives long term diversification into biologics and vaccines
Cost control essential to retain hope of profit growth
SWOT analysis
Strengths
Crestor franchise
Strong track record in cost control
Weaknesses
Over dependent on small molecules
Exposed to cross-class generic substitution
Recent history of pipeline failures
Over dependent on Crestor to drive ‘Core’ growth
Opportunities
Diversification into biologics and vaccines via MedImmune
Cost restructuring strategy
Potential blockbusters in late stage pipeline
Collaborations to boost near-medium term sales forecasts
Threats
Very high exposure to generic competition
No margin for failure in late stage R&D pipeline
Lack of strategic manoeuvrability stemming from MedImmune acquisition
Crestor patent case
Table of Contents
Table of figures
Chapter 3 Quarterly update
Latest comment
Q3 2009
AstraZeneca and Boehringer Ingelheim steal limelight at European Society of Cardiology meeting
Q2 2009
Merck and AstraZeneca: rivals join forces in oncology
Q1 2009
MAP Pharmaceuticals/AstraZeneca: setback for budesonide
AstraZeneca: nasal flu vaccine submitted for European approval
Latest prescription pharma product news
Q4 2009
Q3 2009
Q2 2009
Q1 2009
Latest corporate news
Q4 2009
Q3 2009
Q2 2009
Q1 2009
Future product milestones
Chapter 4 Company introduction
Key findings
Background
M&A history
Astra AB and Zeneca Group plc
Subsequent M&A activity
Abgenix
Cambridge Antibody Technology (CAT)
KuDOS Pharmaceuticals
Arrow Therapeutics
MedImmune
Albireo
M&A strategy
Chapter 5 Company sales
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003-15
Product analysis
Product analysis, 2003-09
Product analysis, 2009-15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009-15
Core analysis, 2009-15
Expiry analysis, 2009-15
Launch/core/expiry configuration, 2009-15
Molecule type analysis
Externalization analysis
Chapter 6 Company financials
Key findings
Note regarding full year 2009 financial data
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08
Operating costs and profit analysis
Operating costs and profit analysis, 2002-08
Operating cost ratio and profit margin analysis, 2002-08
Operating cost ratio and profit margin analysis, 2008-14
Operating costs and profit analysis, 2008-14
Chapter 7 Key products
Overview
Crestor
Summary
Sales forecast
Brilinta
Summary
Sales forecast
Onglyza
Summary
Sales forecast
Certriad
Summary
Sales forecast
Dapagliflozin
Summary
Sales forecast
Seroquel
Summary
Sales forecast
Nexium
Summary
Sales forecast
Seloken/Toprol XL
Summary
Sales forecast
Pulmicort
Summary
Sales forecast
Arimidex
Summary
Sales forecast
Chapter 8 Appendix
References
Abbreviations
Exchange rates
About Datamonitor
About Datamonitor Healthcare
Datamonitor consulting
Disclaimer
ABBREVIATIONS
Browse all : Healthcare Market Research Reports
http://www.reportsandreports.com/cat/healthcare-market-research.html
Browse all : Datamonitor Market Research Reports
http://www.reportsandreports.com/Publisher/datamonitor-market-research.html-market-research.html
Browse all Newly Published Market Research Reports
http://www.reportsandreports.com/LatestReport.aspx
Original Source : PharmaVitae Market
http://www.reportsandreports.com/reports/7951-astrazeneca-plc-pharmavitae-profile.html
Buy Now : Market Research Report
http://www.reportsandreports.com/
Related Reports:
AstraZeneca Plc-Detailed Product Pipeline
http://www.reportsandreports.com/reports/3727-astrazeneca-plc-detailed-product-pipeline.html
AstraZeneca plc-Deals & Alliances Report
http://www.reportsandreports.com/reports/4165-astrazeneca-plc-deals-alliances-report.html
AstraZeneca Plc-Therapeutic Competitors
http://www.reportsandreports.com/reports/3293-astrazeneca-plc-therapeutic-competitors.html
AstraZeneca PLC – SWOT Analysis
http://www.reportsandreports.com/reports/2058-astrazeneca-plc-swot-analysis.html
Shire plc: PharmaVitae Profile
http://www.reportsandreports.com/reports/8599-shire-plc-pharmavitae-profile.html
About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
